Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.34Last Year’s EPS
-1.33Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -3.06%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant regulatory progress and strategic partnerships for aficamten, a strong financial position, and pipeline advancements. However, increased expenses and ongoing regulatory challenges were noted. Despite these challenges, the progress and strategic moves position the company well for future growth.Company Guidance
During Cytokinetics' Fourth Quarter 2024 Conference Call, several key metrics and updates were shared. The company highlighted that their NDA for aficamten was accepted by the FDA with a PDUFA date of September 26, 2025, and the MAA was validated by the EMA, with priority review given in China. They are preparing for potential commercial launches across multiple geographies, including the U.S. and Europe, and have ongoing regulatory interactions. Financially, Cytokinetics ended the quarter with $1.2 billion in cash and investments, and they expect 2025 GAAP operating expenses to range between $670 million and $710 million. The company's R&D expenses for Q4 2024 were $93.6 million, and G&A expenses were $62.3 million. Additionally, Cytokinetics is advancing its clinical programs with MAPLE-HCM, ACACIA-HCM, and COMET-HF, and has formed strategic partnerships with Sanofi and Bayer to expand aficamten's global reach. They also launched an unbranded disease awareness campaign, "HCM Beyond The Heart," to increase awareness of hypertrophic cardiomyopathy (HCM).Regulatory Progress for Aficamten
NDA accepted by FDA, MAA validated by EMA, and NDA accepted by NMPA in China with priority review. Engaging in parallel regulatory interactions for potential global approvals.
Strategic Partnerships
Entered a collaboration with Bayer for aficamten in Japan, securing EUR50 million upfront and potential EUR490 million in commercial milestone payments. Additionally, Sanofi acquired rights to aficamten in China.
Financial Strength
Ended Q4 2024 with $1.2 billion in cash and investments. Generated $16.9 million in revenue in Q4 2024, a significant increase from $1.7 million in Q4 2023.
Pipeline Advancements
Started COMET-HF Phase 3 trial for omecamtiv mecarbil and AMBER-HFpEF Phase 2 trial for CK-586. Initiated Phase 1 study for CK-089, a neuromuscular disease candidate.
---
CYTK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CYTK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $47.45 | $46.00 | -3.06% |
| Nov 06, 2024 | $55.50 | $55.84 | +0.61% |
| Aug 08, 2024 | $54.00 | $55.79 | +3.31% |
| May 08, 2024 | $65.27 | $64.02 | -1.92% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cytokinetics (CYTK) report earnings?
Cytokinetics (CYTK) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Cytokinetics (CYTK) earnings time?
Cytokinetics (CYTK) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CYTK EPS forecast?
CYTK EPS forecast for the fiscal quarter 2025 (Q1) is -1.34.
---